Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

A federal judge on Tuesday allowed parts of that lawsuit to move forward, finding that investors had plausibly alleged that some statements about CagriSema's tolerability and the design of the late-stage trial may have been misleading. The ruling does not determine that Novo committed securities fraud. Instead, it means the case can proceed into the next stage, where investors can seek evidence supporting their claims.A Novo Nordisk spokesperson said the company "believes that the allegations against it are meritless," and intends to vigorously defend against them. It comes as Novo works to boost investor confidence in its obesity business amid mounting competition from Eli Lilly and as it bets heavily on its next generation of weight-loss treatments.Here's what happened, what the lawsuit alleges, and why CagriSema has become so important to Novo's future. What investors allege The case centers on CagriSema, an experimental weekly injection that combines semaglutide — the active ingredient in Wegovy and Ozempic — with cagrilintide, which mimics the hormone amylin.When Novo released CagriSema topline results in December 2024, investors had widely expected the treatment to produce av...